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Abstract Cancer is a complex disease involving
many different genomic and epigenomic changes,
mutations, copy number changes, loss of heterozy-
gosity etc. These differences cause tumorswith the same
pathological classification to respond very differently
to the drugs, making therapy decisions difficult. As a
result of intensive research in the field of oncology
much information is available on molecular interac-
tions and pathways involved in cancer onset and
progression. In addition recent increases in the
capacity of next-generation sequencing systems will
provide huge amounts of genome, epigenome and
transcriptome data, making it feasible to apply deep
sequencing in the clinic to characterize tumor/patient
samples. Both, the complexity of disturbances in
interaction networks of biological processes in cancer
and the newmolecular information generated by this
sequence analysis urgently require the development
of systems that are able to derive clinically relevant
predictions from all available data. The ‘‘Virtual
Patient’’ modeling system combines general informa-
tion available about cancer relevant pathwayswith the
individual (genome, transcriptome) information
available on the individual tumor/patient to generate
models able to predict the effects and side effects of
individual drugs or drug combinations. This opens the
way to experiment with the response of the model of
the individual patient to different therapy options in
the computer, offering new routes to improve onco-
logical practice, reduce health costs but also to
accelerate the development and the approval process
for new drugs in this area.
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1 Introduction
With *12 million new cancer cases per year world-
wide cancer is expected to overtake heart disease as
the leading cause of death worldwide in 2010 (Boyle
and Levin 2008). The basic general mechanisms of
cancer are already well known. Research both in
clinic and in the lab has clearly shown that cancer is a
disease that develops over time as a result of an
accumulation of many factors that promote tumor
growth and metastasis (Hanahan and Weinberg
2000). Cure rates for most common forms of cancer
have however hardly changed over the last decades.
Experience in sequencing tumor genomes both by us
and by others have shown that tumors typically have
thousands of somatic changes and that many more
gene mutations drive the development of cancer
than previously thought (Greenman et al. 2007).
These many alterations make every tumor different,
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causing every patient to respond differently to spe-
cific therapies. Thus even tumors from the same
clinical classification may require very different
treatments.
Up to now more than 350 genes have been iden-
tified, whose mutations or other genetic alterations
are causally implicated in cancer development and
hence are known as ‘cancer genes’ (Greenman et al.
2007). These genes offer starting points for the
development of innovative drugs and new therapies.
However, the actual molecular blueprint of each
individual cancer is poorly known, mostly because
until now, only a few known mutations could be
monitored in tumors, without any knowledge of the
transcriptional landscape, or of the global genome
alterations including numerous somatic mutations,
aneuploidy status, genome instability and epigenetic
changes. For this reason even the most advanced
targeted therapies developed so far are typically only
effective for a small fraction of patients primarily due
to molecular differences between different tumors. It
has often been shown that the effectiveness of specific
targeted therapies depends on the presence or
absence of specific changes. It has for example been
shown, that the overexpression or the presence of an
activating mutation in the epidermal growth factor
receptor (EGFR) is a strong predictor of a response of
the tumor to the drug Gefitinib (Mok et al. 2009).
Similarly the hormone receptors and HER2 status in
breast cancer (Taneja et al. 2010) or the presence or
absence of KRAS wild type or BRAF wild type have
been used for individualized therapy recommenda-
tions (Di Nicolantonio et al. 2008; Karapetis et al.
2008; Van Cutsem et al. 2010; Wilson et al. 2010).
However, since hundreds of mutated genes or genetic
alterations are implicated in cancer development, in
many other indications e.g. ovarian cancer (Hays et al.
2010) or the renal cell carcinoma (Cheng et al. 2010;
Shah and Margulis 2010) little progress has been
made. Even targeted diagnostics like the KRAS assay
are only providing a relatively small improvement,
e.g. the KRAS diagnostic improves the response rate of
the corresponding EGFR inhibitor/Irinotecan therapy
in second-line colon cancer from 10 % for the KRAS
mutant group to a 35 % for the KRAS wild type group
(Amgen 2009), due to other mutations or other
genetic alterations beside KRAS and BRAF, such as a
PIK3CA mutation or a loss of PTEN expression (Jhawer
et al. 2008), that counteract the drug response. This
example underscores the urgent need for a more
accurate, reproducible and systematic approach for
new diagnostic biomarkers that are more informative
in predicting the response of the tumor to specific
therapies.
Since it is expected by 2030 that there could be 27
million incident cases of cancer, 17 million cancer
deaths annually and 75 million persons alive with
cancer within five years of diagnosis (Boyle and Levin
2008) and the development costs of new cancer drugs
have dramatically increased, while the number of new
drug approvals in this area keep dropping, both the
public health system as well as the pharmaceutical
industry are facing big challenges. Therefore a system
is needed that on the one hand helps to select the right
drug (or drug combination) for each patient, but also
identifies the ‘right’ patient (population) for each
drug, reducing the size of clinical studies required to
detect a positive response, and decreasing develop-
ment costs of new cancer drugs.
Two significant developments allow us to take a
more integrated approach for selecting appropriate
cancer therapies for patients by predicting effects
(and side effects) of different drugs/drug combina-
tions on individual patients:
• As a result of decades of cancer research many
signaling pathways considered relevant to cancer
have been characterized, as illustrated in the
‘‘Pathways of Human Cancer’’ poster showing the
molecular interactions of hundreds of proteins
(Weinberg 2007). Databases on cellular interaction
networks with functional information of cellular
systems have been established, such as Reactome
(Joshi-Tope et al. 2005) and KEGG (Kanehisa et al.
2004). Moreover the molecular effects of somatic
mutations observed in many types of cancer have
been characterized and different comprehensive
databases have been set up, e.g. the Catalogue Of
Somatic Mutations In Cancer (COSMIC), which
integrates information on cancer associated muta-
tions (Forbes et al. 2006).
• Since the completion of the first human genome
sequence (Lander et al. 2001; IHGSC 2004) new
sequencing technologies have been developed.
These next-generation sequencing (NGS) technol-
ogies provide an increase in sequencing
throughput and a decrease in per base pair
sequencing costs at the same time (Brenner et al.
2000; Schuster 2008), which now allow the appli-
cation of genome scale analysis to the tumor and
somatic tissue of each cancer patient. Extrapolat-
ing current trends in sequencing costs, full genome
sequencing would be within the reach of the mass
markets within the next few years.
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The combination of global information on can-
cer relevant pathways and detailed characterization
of patient’s tumor material by deep sequencing
now allows, for the first time, the development of
predictive models of the onset and the progression
of cancer as well as the drug response in individual
cancer patients. Systems biology offers computa-
tional tools to analyze, integrate and interpret
biological data, and provides mathematical and
computational concepts for the development,
simulation and interpretation of cellular interaction
networks (Wierling et al. 2007; Bois 2009; Chen
et al. 2009; Klipp et al. 2009). Most of these models
(as collected in the BioModels database) address
individual pathways (metabolic processes, individ-
ual signal transduction pathways, cell cycle
regulation). Tumors have however changes in many
components of the relevant biological networks.
Similarly, most drugs used in oncology interact in a
complex pattern with many different proteins,
binding to different (main or side) targets with
different dissociation constants. Realistic models of
therapy effects therefore have to cover more com-
plex situations than usually addressed in systems
biology.
Although models on tumor cellular evolution
have been developed, such as a stochastic mathe-
matical model of the evolution of tumor metastases
in an expanding cancer cell population (Haeno and
Michor 2010) or a model that describes the accu-
mulation of driver (and passenger) mutations during
tumor development (Bozic et al. 2010), there is no
approach in cancer modeling available that can
model very large pathway systems with consider-
ation of patient specific environment. But since
many of the cancer drugs available are only effec-
tive in an often rather small fraction of the patient
population, with the majority of patients showing
little or no benefits or even suffering often quite
severe side effects shows that the progress in the
treatment of tumors in individual patients will
depend critically on being able to predict the effect
of such treatments in the context of the genome/
transcriptome involved. We therefore developed a
system that is capable of handling the complexity of
biological processes like cancer even in the absence
of accurate knowledge on kinetic parameters (which
are typically unknown) and has the unique oppor-
tunity to be fuelled with massive patient specific
molecular data arise from NGS analysis and thereby
is able to predict effects and side effects of drugs
and drug combinations in individual tumor
patients: the ‘‘Virtual Patient’’ system.
2 Detailed molecular characterization of tumors
using NGS technologies
The molecular characterization of tumor has devel-
oped from the systematic sequencing of segments
coding for candidate genes or gene families by San-
ger sequencing to whole genome sequencing based
on NGS techniques (Wood et al. 2007; Parmigiani
et al. 2009; Pleasance et al. 2010a, b). These tech-
niques also offer a new way in which cancer patient
samples can be analyzed. RNAseq provides compre-
hensive RNA expression profiles with qualitative
and quantitative information relative to transcript
expression levels including that of rare transcripts,
small RNAs and novel transcribed units, alternative
splicing, allele specific expression patterns and RNA
editing (Sultan et al. 2008; Richard et al. 2010). Due to
improvements of RNAseq protocols the routine
analysis of the strand specificity (Parkhomchuk et al.
2009), as well as paired end read information can be
generated.
Therefore RNAseq studies on cancer cells and
tumors are now increasingly performed (Berger et al.
2010; Stark et al. 2010) showing that both genome
and transcriptome information are essential to
establish an accurate correlation with the phenotype
of the tumor. For example, in the case of a tumor
suppressor gene mutated on one chromosome,
whereas the second (non-mutated) copy silenced by
epigenetic processes, the loss of functioning allele
will be only detected by analyzing allele specific
expression patterns.
In addition to the molecular analysis of the bulk
tumor, the molecular characterization of cancer stem
cells (CSC) can be of high value, despite the contin-
uing debate over their definition, how common they
are, and whether they even exist. CSC are proposed to
originate either from malignant transformation of a
normal or a progenitor cell (Reya et al. 2001), to have
self-renewal capacities and, since they proliferate
throughout life, to be more susceptible to accumu-
lation of oncogenic mutations than differentiated
cells with their comparatively short life span (Mon-
zani et al. 2007) and thereby more resistant than the
rest of the tumor cells. It is believed that a cancer
recurrence occurs because even one single cell that
evades the surgeon’s blade or a chemotherapy or
radiation by its hardiness is enough to recapitulate
the whole tumorigenesis. It is therefore likely that
CSC harbor quite different molecular characteristics
than bulk tumor, and require to be treated differently
in order to be killed. We have already applied this
deep molecular characterization technology on a
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specific patient, a metastatic melanoma patient. For
this patient, both the genomes of the bulk tumor and
blood were extensively characterized by deep
sequencing with a 409 and 309 coverage respec-
tively (*120 gigabases tumor,*90 gigabases blood).
In addition, a detailed analysis of the transcriptome
of the tumor, tumor derived cell lines, and cancer
stem cells (selected by growth in ES cell media, fol-
lowed by magnetic bead selection using antibody
against the cell surface antigen CD133, often associ-
ated with cancer stem cells) from the same patient, as
well as melanocyte cell line as control, were carried
out (*300 million reads in total). This combined
RNAseq and genome analysis supplies molecular
information about one specific tumor in unprece-
dented quantity and provides an ultra-deep analysis
of a melanoma molecular landscape: More than 1,000
somatic mutations were detected in this patient, of
which more than 100 affected expressed coding
regions, more than 1,000 genes were induced and
over a dozen of autocrine loops were identified that
are potential drivers of the tumor (manuscript in
preparation).
3 Modeling cancer using the ‘‘Virtual Patient’’
system
The ‘‘Virtual Patient’’ system is based on the modeling
and simulating system PyBioS (Wierling et al. 2007)
and uses relatively conventional mathematical path-
way modeling approaches. It is written in an object
oriented programming language (Python) and is
designed so that the objects correspond to the com-
ponents of the pathways relevant for cancer (genes,
proteins, DNA and protein modification states, com-
plexes, metabolites etc). Each object is assigned to
keep track of its state (e.g. concentration) as well as its
functions (e.g. to phosphorylate another protein
object at a specific amino acid, to form a complex
with a specific dissociation constant). The system is
initialized with the starting concentrations of all
components, as well as values of the kinetic constants
in these differential equations, allowing the system to
be solved numerically. The resulting computations
allow analysis of both the kinetic changes, as well as
the concentrations of the relevant products in the
steady state after a perturbation such as a mutation
or an autocrine loop. Since many kinetic parameters
are unknown, or have at best been determined under
laboratory conditions far from the situation in the
tumor environment, a Monte-Carlo-based simulation
approach is used. In this strategy the kinetic
parameters are sampled from appropriate probabil-
ity distributions and are used for multiple
simulations in parallel. Simulation results from dif-
ferent forms of the model (e.g. a model that
resembles a certain mutation pattern) can be com-
pared with an unperturbed control and used for the
prediction of the effect of the perturbation (Wierling
et al. 2011). The backbone of the ‘‘Virtual Patient’’
model contains several cancer relevant signaling
pathways as proposed by Hanahan and Weinberg
(Hanahan and Weinberg 2000; Weinberg 2007) plus
additional signaling pathways available from path-
way databases, like BioCyc (Karp et al. 2005), KEGG
(Kanehisa et al. 2004), Reactome (Joshi-Tope et al.
2005; Vastric et al. 2007) and ConsensusPathDB
(Kamburov et al. 2009). By rigorous literature
screening using different resources, like PubMed,
GeneCards, iHOP and Bibliosphere, molecular inter-
action details were added when required. Overall, in
the developed modeling system up to date about 30
different signaling pathways are implemented,
amongst others cytokine signaling (e.g. CSF, IFNA,
IL8), death receptor signaling (e.g. Fas, TNFa, Trail),
DNA repair/cell cycle, ephrin signaling, GCPR/hor-
mone signaling (e.g. insulin, progesterone,
testosterone), hedgehog signaling, notch signaling,
several RTK signaling (e.g. bNGF, EGF, FGF, IGF, PDGF,
VEGF), TGFb signaling (e.g. BMP, TGFb) and Wnt sig-
naling. At the moment the model covers more than
400 genes (reflecting over 2,000 paralogues), corre-
sponding to more than 2,000 components. The
potential effects of more than 50 different mutations
(loss of function, activating and fusion) in several
genes have been implemented (e.g. BCR-ABL, KRAS),
and the potential effects of about 50 extra-cellular
stimuli, such as growth factors (e.g. IGF, VEGF), hor-
mones (e.g. testosterone) and organic compounds
(e.g. phorbol esters) as well as almost 40 different
inhibitors (e.g. EGFR inhibitor, MEK inhibitor) have
been introduced. In total, these different components
are connected to more than 3,000 reactions giving
rise to over 3,500 kinetic parameters. Patient specific
molecular data and clinical information were then
used to generate a comprehensive individual model
of the biology of the tumor, as well as key tissues of
the patient in the ‘‘Virtual Patient’’ system. Levels of
transcripts can be directly set based on the RNAseq
results. Concentrations of specific proteins or protein
modification states can be either based on proteomic
results, or (with unavoidable uncertainty) estimated
from protein synthesis rates assumed to be propor-
tional to transcript levels, counterbalanced by a
constant protein degradation rate. Secondly, RNAseq
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is used to determine whether mutations detected in
the patient’s genome are expressed and must be
modeled or can be ignored. To identify possible
effects on surrogate markers of relevant cellular
phenotypes (e.g. c-Myc for cell division, Casp-3 for
apoptosis) modeling runs comparing the different
conditions (every single mutation, autocrine loop,
splice variant etc.) with a control state (no mutation,
no growth factor) are performed. This allows the
identification of key drivers of specific abilities which
characterize cancer cells, such as sustained angio-
genesis, limitless replicative potential and
insensitivity to anti-growth signals, as proposed by
Hanahan and Weinberg (2000) and to distinguish
between the rare driver mutations and the thousands
of passenger mutations typically found in tumors
(Greenman et al. 2007; Ley et al. 2008; Mardis et al.
2009). By combining all alterations found, this gives a
detailed picture of a patient’s tumor. Having a
patient-specific tumor model (according to the
patient’s mutation pattern and expression profile)
opens up the possibility to predict a patient’s
response on various cancer drugs and drug combi-
nations in silico and to find an optimal personalized
cancer treatment. We therefore created a drug
database, based on knowledge from textbooks, pri-
mary literature and several databases as part of the
‘‘Virtual Patient’’ system. The drug database up to
now contains about 30 different drugs (e.g. Dasatinib,
Erlotinib, Imatinib). Drugs are entered into the model
by initializing appropriate inhibitors according to the
known target proteins of the drug with ideally
known values for dissociation constants (Karaman
et al. 2008). The effect of a drug is analyzed using the
concentration of c-Myc as a surrogate marker for
clinical effectiveness, as elevated levels of this protein
are indicative of cell division. In an automated pro-
cedure first all drugs are analyzed separately
(Round1). In a second round all drugs that showed a
positive effect on the level of c-Myc in Round1 are
analyzed in double combination (Round2). These
steps (Round3 uses triple combination etc.) are
repeated until a drug combination is found that
showed the highest positive effect on the level of
c-Myc. Side effects of a drug/drug combination can be
predict by identifying the effects of drug/drug com-
binations on normal cells stimulated by different
types of growth factors. For this, modeling runs are
carried out for the normal tissue responding to dif-
ferent growth factors in the presence and absence of
a drug/drug combination.
The data of the melanoma patient (see Sect. 2)
have been used to generate a comprehensive model
of the biology of the tumor, as well as the cancer
stem cells in the ‘‘Virtual Patient’’ system. Eight of the
genes to be found mutated were already part of the
model of which five were found to be not expressed
by RNAseq analysis. Two of them could be identified
as key drivers for proliferation. Beyond we could
model the effect of twelve of the identified autocrine
loops of which seven seem to be important for driv-
ing the tumor growth (see Fig. 1). Based on these
mutations and autocrine loops we modeled a patient
specific tumor and performed the drug optimization
program. All individual drugs showed no or only
little effect on the level of c-Myc. Pairwise combina-
tions of effective drugs resulted in some cases in an
increase in synergistic effects. The c-Myc level could
be further reduced by a triple combination. Increas-
ing doses of the optimal drug combination resulted
in a predicted reduction of c-Myc levels to the c-Myc
level predicted for non-stimulated normal cells (see
Fig. 1; manuscript in preparation).
Since for one of the driving mutations found (we
first assumed gain of function), the molecular effect
of the missense mutation were not known, we also
modeled this mutation as both loss of function and
tolerated mutation (wild type function). The model
was able to find that this mutation when not mod-
eled as constitutively activating changed the
sensitivity of the in silico patient’s tumor model. In
this case a combination of two drugs is already suf-
ficient to stop proliferation as indicated by predicted
reduced levels of c-Myc. Subsequent cellular testing
in patient derived tumor cells is used to validate the
predictions of the model. This is powerful example of
how computational modeling coupled with deep
sequencing and integrative bioinformatics analysis
can identify the key drivers in an individual tumor
and can eliminate those mutations that are either
passenger, non-expressed or without impact for
consideration of appropriate therapies.
4 Discussion and outlook
Here we present the ‘‘Virtual Patient’’ system that
effectively provides a place where all current knowl-
edge of cancer pathways and mutations as well as
other relevant knowledge can reside. Using a Monte-
Carlo-based approach it is able to construct accurate
predictive cancer models of much more complex
networks than possible up to now and can thereby
help to improve the understanding on the conse-
quences of cancer related mutations on a molecular
pathway level and their functional effects on the
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cellular and organism level. Together with the com-
plete molecular characterization of the tumor and
somatic genomes and transcriptomes by application
of next generation sequencing of individual cancer
patients, the ‘‘Virtual Patient’’ system combines
everything that can be known about a patient’s dis-
ease with everything that is known about cancer as a
whole as reflected in the patient-specific tumor
model. Due to the rapid development of ultra high
throughput sequencing techniques, promising
sequencing cost of a few hundreds of dollars per
Gigabase, an enormous effect on the use of predictive
modeling for individual tumor fate can be expected.
Hence, it is likely that the detailed molecular analysis
of the genome of a particular cancer (as well as
somatic genome of the patient) becomes a compo-
nent of routine diagnostics in oncology. The impact
on patient care, but also on economic viability, of
personalized medicine approaches using predictive
models has already been demonstrated. Using an ER
response/Herceptin model and a 21-gene assay for
breast cancer and through meta-analysis of a series
of studies it was shown that the 21-gene assay is not
only prognostic for recurrences, but can also predict
the impact of chemotherapy and chemotherapy
ineffectiveness. Specifically, chemotherapy benefit
was restricted to patients with high-Recurrence Score
(RS), while cases with low-RS, despite having other
clinical features of higher risk, had virtually no ben-
efit from chemotherapy. Using such an approach it
was possible to demonstrate significant overall
savings – although the testing cost ca. $7,000/pt. The
savings were ascribed to: a substantially lower num-
ber (20–35 %) of patients receiving chemotherapy and
a higher overall survival rate due to the addition of
curative chemotherapy to the 5 % of high-RS patients,
otherwise considered in the pre-RS testing practice
for treatment with hormones alone (Tsoi et al. 2010).
Currently the ‘‘Virtual Patient’’ system is being used
in the EU/EFPIA funded Innovative Medicine Initia-
tive, OncoMark, to integrate high throughput ‘omics’
data and to guide the treatment of 60 cancer patients
with non-metastatic colon cancer and in the German
BMBF funded, TREAT20 project, where it is providing
treatment recommendations for 20 metastatic mela-
noma patients based on patient’s ‘omics’ data.
Another potential saving is given by the capacity
of the ‘‘Virtual Patient’’ system to detect new bio-
markers and new drug targets. It is suggested that
the KRAS mutational status of metastatic colorectal
cancer is predictive for the patient’s response to an
anti-EGFR therapy and that a routine KRAS analysis
Fig. 1 A ‘virtual’ patient modeled according to the patient’s
mutation pattern and expression profile shows predictions of
changes in key components of the model under different
conditions (stimulation with growth factors, mutations, different
drugs and drug combinations at different concentrations). The
results show mean ratios of specific treatment experiments vs. a
control state (no growth factor, no mutation, no drug). The
effects of three mutations of the selected genes as well as the
twelve autocrine loops in the patient were simulated individually
and in combination to model a tumor of a specific melanoma
patient. The model predicts a high c-Myc concentration in the
tumor indicating a high rate of cell division. All individual drugs
show no or only little effect on the level of c-Myc. Increasing
doses of a combination of drugs in contrast can block c-Myc
expression in the tumor, expected to stop cell division
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would exclude 30–40 % of patients from anti-EGFR
therapy, resulting in a potential financial saving of
hundreds of millions of dollars (Patil et al. 2010).
Importantly they go on to note, however, that a sig-
nificant proportion of KRAS wild-type tumors do not,
in fact, respond to anti-EGFR therapy and that addi-
tional testing of other genes or proteins within the
EGFR signaling pathway will probably be required to
help guide better patient selection. Since the ‘‘Virtual
Patient’’ system integrates the complete patient’s
‘omics’ data, it is expected that new markers beside
KRAS can be identified and that an EGFR panel will
become standard practice prior to initiating anti-
EGFR therapy. Thus, more patients can escape a
therapy they do not benefit from (or even make them
more sick) and the public health system is financially
relieved. A generation of novel markers will be also of
significant advantage for patient stratification and/or
therapy monitoring during clinical trials. The use of
highly characterized markers, derived from a sys-
tematic analysis of a tumor type (e.g. breast, lung,
colon) could dramatically impact the design of such
clinical trials. One might expect a significant reduc-
tion in the number of patients required to assess new
therapeutic agents – since the biomarkers selected
would reflect the specific pathways impacted by the
therapeutic agent. Likewise one could envisage dra-
matically shorter clinical trial times. Both scenarios
would significantly reduce the lab bench – to patient
bedside time, and markedly improve the efficiency of
drug discovery for the pharmaceutical industry. The
combined result of these effects would be to cap the
spiraling costs of health care by yielding more effi-
cacious drug use in the clinic and a reduced drug
development time. In the field of biomarker/drug
target discovery the ‘‘Virtual Patient’’ system is
already involved in four projects: In the EU/EFPIA
funded Innovative Medicine Initiative, OncoMark, is
it used to identify biomarkers for colon cancer by
analyzing a cohort of 60 colon carcinoma patients; in
the project ‘‘Systems biology of prostate cancer’’
funded by the Austrian Nationalstiftung and the
Austria Wirtschaftsservice GmbH in the framework
of the IMGuS research program, where it supports
the detection of prostate specific biomarkers for the
prognosis of prostate cancer risk by integrating high-
throughput ‘omics’ data of 50 prostate cancer
patients into personalized computer models; and in
the PREDICT project funded within the MedSys pro-
gram of the BMBF, where it is used for the prediction
of success of targeted therapies (e.g. cetuximab and
erlotinib) on pre-clinical in vitro and in vivo models
for lung cancer. In the MUTANOM project the
‘‘Virtual Patient’’ system is used to integrate data
from mutational profiling, transcriptome and prote-
ome data from breast/prostate/gastroentestinal
cancer cells and to develop predictive models for the
clinical use of chemotherapeutics, environmental
determinants on diseases as well as for predicting
disease progression in general.
The ‘‘Virtual Patient’’ system is a powerful weapon
against cancer by finding an optimal drug/drug
combination for individual cancer patient treatments
and predicting new drug targets and diagnostic
biomarkers resulting in improved cure rates in neo-
plastic disease.
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